Atorvastatin-induced Lupus Erythematosus Tumidus: A Case Report and Literature Review

Acta Dermatovenerol Croat. 2023 Dec;31(3):125-132.

Abstract

Lupus erythematosus tumidus (LET) is a rare photosensitive skin disease classified as a separate subtype of cutaneous lupus erythematosus. Clinically, it is characterized by erythematous plaques on sun-exposed areas. Typical histopathological findings are perivascular and periadnexal lymphohistiocytic infiltrates and prominent mucin deposition in the dermis. Treatment is based on photoprotection, topical corticosteroids, and antimalarial drugs. The exact pathogenesis of the disease is unknown. Drugs are considered a minor risk factor for the development of LET. We present a case of a 56-year-old woman who developed LET after starting treatment with atorvastatin. We describe her clinical course and review the literature concerning the cutaneous adverse reactions induced by statin drugs. To our knowledge, this is the first case of statin-induced LET. We conclude that statins can induce LET and that it is important for clinicians to be aware of this potential adverse effect associated with statins.

Publication types

  • Review
  • Case Reports

MeSH terms

  • Antimalarials* / adverse effects
  • Atorvastatin / adverse effects
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
  • Lupus Erythematosus, Cutaneous* / chemically induced
  • Lupus Erythematosus, Cutaneous* / diagnosis
  • Lupus Erythematosus, Discoid*
  • Middle Aged

Substances

  • Atorvastatin
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Antimalarials